Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin
Antibody Therapeutics · 29.06.2026 · 9 (3) · 460-470
DOI: 10.1093/abt/tbag036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 08.07.2026. Verfasst von Yidan Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: RemeGen Co. Ltd, No. 58 Beijing Middle Road, Yantai, Shandong 264006, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Postdoctoral Innovation Program of Shandong Province, Shandong Provincial Key Laboratory of Antibody Drugs Program, Shandong Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Mesothelin (MSLN) is a therapeutic target for antibody–drug conjugates (ADCs) due to its tumor-selective overexpression. However, soluble MSLN (sMSLN) in circulation compromises efficacy by acting as a decoy. RC88 is a clinical-stage ADC composed of a humanized anti-MSLN antibody conjugated to a monomethyl auristatin E (MMAE) payload. This study elucidates the unique binding mechanism that allows RC88 to maintain superior efficacy despite sMSLN interference.
Methods
We characterized the RC88–MSLN interaction via structural analysis and mutagenesis. The impact of sMSLN on binding was assessed using competitive cellular assays. In vitro internalization kinetics and cytotoxicity were evaluated to determine the therapeutic potential.
Results
RC88 targets a high-affinity N-terminal epitope overlapping the MUC16/CA125-binding site, competitively inhibiting this interaction. Notably, due to the structural flexibility of MSLN, RC88 also engages a secondary, low affinity juxtamembrane epitope at the C-terminus. This conformational binding confers resistance to sMSLN interference and enhanced tumor cell retention. In vitro, RC88-ADC maintained near-complete cytotoxic potency even in the presence of physiologically relevant sMSLN concentrations. In vivo, RC88 suppressed tumor growth in ovarian cancer xenografts.
Conclusion
Our findings demonstrate that RC88 utilizes a novel conformational binding strategy to overcome the limitations of soluble antigen interference. These findings provide a mechanistic rationale for the encouraging clinical activity of RC88 and suggest that conformational epitope targeting represents a promising strategy for overcoming sMSLN interference in MSLN-positive cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RemeGen Co. Ltd, No. 58 Beijing Middle Road, Yantai, Shandong 264006, China.
- RemeGen (Shanghai) Co. Ltd, Tianxiong Road, Pudong New Area, Shanghai 201318, China.
- RemeGen Biosciences, Inc, 650 Gateway Blvd, Suite 110, South San Francisco, CA 94080, United States.
Förderung
- Postdoctoral Innovation Program of Shandong Province
- Shandong Provincial Key Laboratory of Antibody Drugs Program
- Shandong Postdoctoral Science Foundation
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
- Shandong Provincial Natural Science Foundation
Zitieren
APA
Xu, Y., Li, M., Wang, L., Wang, K., Wang, X., Zhang, X., Yu, Z., Xin, Y., He, C., He, X., Zhou, J., Min, X., Chen, H., Wang, Z., Li, D., Fang, J., & Li, Y. (2026). Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin. Antibody Therapeutics, 9(3), 460-470. https://doi.org/10.1093/abt/tbag036
Vancouver
Xu Y, Li M, Wang L, Wang K, Wang X, Zhang X, et al. Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin. Antibody Therapeutics. 2026;9(3):460-470. doi:10.1093/abt/tbag036
BibTeX
@article{Xu2026,
author = {Xu, Yidan and Li, Mingyang and Wang, Lili and Wang, Kailin and Wang, Xiao and Zhang, Xiaoping and Yu, Zhanjiao and Xin, Yinghao and He, Chenglin and He, Xiangyi and Zhou, Jing and Min, Xiaoshan and Chen, Hang and Wang, Zhulun and Li, Dong and Fang, Jianmin and Li, Yuanhao},
title = {Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {460--470},
doi = {10.1093/abt/tbag036}
}
EUVIMED